Flecainide therapy reduces exercise-induced ventricular arrhythmias in patients with catecholaminergic polymorphic ventricular tachycardia

Journal of the American College of Cardiology

Volumn 57, Issue 22, 2011, Pages 2244-2254

  Van Der Werf, Christian ^a   Kannankeril, Prince J ^c   Sacher, Frederic ^e   Krahn, Andrew D ^f   Viskin, Sami ^g   Leenhardt, Antoine ^h   Shimizu, Wataru ⁱ   Sumitomo, Naokata ^j   Fish, Frank A ^c   Bhuiyan, Zahurul A ^b   Willems, Albert R ^a   Van Der Veen, Maurits J ^k   Watanabe, Hiroshi ^l   Laborderie, Julien ^m   Hassaguerre, Michel ^e   Knollmann, Bjrn C ^d   Wilde, Arthur A M ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c MONROE CARELL JR CHILDREN S HOSPITAL AT VANDERBILT   (United States)

^d VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e BORDEAUX UNIVERSITY HOSPITAL   (France)

^f UNIVERSITY OF WESTERN ONTARIO   (Canada)

^g TEL AVIV UNIVERSITY   (Israel)

^h HÔPITAL LARIBOISIÈRE   (France)

ⁱ NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

^j NIHON UNIVERSITY   (Japan)

^k GELDERSE VALLEI HOSPITAL   (Netherlands)

^l NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

^m Bayonne Medical Center   (United States)

more..

Author keywords

antiarrhythmia agents; catecholaminergic polymorphic ventricular tachycardia; ventricular arrhythmia

Indexed keywords

ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CALCIUM CHANNEL BLOCKING AGENT; CARVEDILOL; FLECAINIDE; METOPROLOL; NADOLOL; SOTALOL; VERAPAMIL;

ADOLESCENT; ADULT; AGED; ARTICLE; CALCIUM TRANSPORT; CATECHOLAMINERGIC POLYMORPHIC VENTRICULAR TACHYCARDIA; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DEFIBRILLATOR; DIZZINESS; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EXERCISE TEST; FATIGUE; FEMALE; HEART VENTRICLE ARRHYTHMIA; HUMAN; MALE; NAUSEA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SCHOOL CHILD; SINUS ARREST; THORAX PAIN; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; ANTI-ARRHYTHMIA AGENTS; ARRHYTHMIAS, CARDIAC; CHILD; DEFIBRILLATORS, IMPLANTABLE; DOSE-RESPONSE RELATIONSHIP, DRUG; EXERCISE TEST; FEMALE; FLECAINIDE; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TACHYCARDIA, VENTRICULAR; YOUNG ADULT;

EID: 79957553666     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2011.01.026     Document Type: Article

References (37)

1. A. Leenhardt, V. Lucet, I. Denjoy, F. Grau, D.D. Ngoc, and P. Coumel Catecholaminergic polymorphic ventricular tachycardia in children A 7-year follow-up of 21 patients Circulation 91 1995 1512 1519
2. M. Hayashi, I. Denjoy, and F. Extramiana Incidence and risk factors of arrhythmic events in catecholaminergic polymorphic ventricular tachycardia Circulation 119 2009 2426 2434
3. S.G. Priori, C. Napolitano, and M. Memmi Clinical and molecular characterization of patients with catecholaminergic polymorphic ventricular tachycardia Circulation 106 2002 69 74 (Pubitemid 34747444)
4. S.G. Priori, C. Napolitano, and N. Tiso Mutations in the cardiac ryanodine receptor gene (hRyR2) underlie catecholaminergic polymorphic ventricular tachycardia Circulation 103 2001 196 200 (Pubitemid 32095402)
5. H. Lahat, E. Pras, and T. Olender A missense mutation in a highly conserved region of CASQ2 is associated with autosomal recessive catecholamine-induced polymorphic ventricular tachycardia in Bedouin families from Israel Am J Hum Genet 69 2001 1378 1384 (Pubitemid 33124218)
6. A. Medeiros-Domingo, Z.A. Bhuiyan, and D.J. Tester The RYR2-encoded ryanodine receptor/calcium release channel in patients diagnosed previously with either catecholaminergic polymorphic ventricular tachycardia or genotype negative, exercise-induced long QT syndrome: a comprehensive open reading frame mutational analysis J Am Coll Cardiol 54 2009 2065 2074
7. D. Jiang, B. Xiao, and D. Yang RyR2 mutations linked to ventricular tachycardia and sudden death reduce the threshold for store-overload-induced Ca2+ release (SOICR) Proc Natl Acad Sci U S A 101 2004 13062 13067 (Pubitemid 39167583)
8. M.R. di Barletta, S. Viatchenko-Karpinski, and A. Nori Clinical phenotype and functional characterization of CASQ2 mutations associated with catecholaminergic polymorphic ventricular tachycardia Circulation 114 2006 1012 1019 (Pubitemid 44358877)
9. B.C. Knollmann, N. Chopra, and T. Hlaing Casq2 deletion causes sarcoplasmic reticulum volume increase, premature Ca2+ release, and catecholaminergic polymorphic ventricular tachycardia J Clin Invest 116 2006 2510 2520 (Pubitemid 44330150)
10. M. Cerrone, S.F. Noujaim, and E.G. Tolkacheva Arrhythmogenic mechanisms in a mouse model of catecholaminergic polymorphic ventricular tachycardia Circ Res 101 2007 1039 1048 (Pubitemid 350084981)
11. B. Bauce, A. Rampazzo, and C. Basso Screening for ryanodine receptor type 2 mutations in families with effort-induced polymorphic ventricular arrhythmias and sudden death: early diagnosis of asymptomatic carriers J Am Coll Cardiol 40 2002 341 349 (Pubitemid 34756298)
12. N. Sumitomo, K. Harada, and M. Nagashima Catecholaminergic polymorphic ventricular tachycardia: electrocardiographic characteristics and optimal therapeutic strategies to prevent sudden death Heart 89 2003 66 70 (Pubitemid 36044293)
13. A.V. Postma, I. Denjoy, and J. Kamblock Catecholaminergic polymorphic ventricular tachycardia: RYR2 mutations, bradycardia, and follow up of the patients J Med Genet 42 2005 863 870 (Pubitemid 41598196)
14. H. Lahat, M. Eldar, and E. Levy-Nissenbaum Autosomal recessive catecholamine- or exercise-induced polymorphic ventricular tachycardia: clinical features and assignment of the disease gene to chromosome 1p13-21 Circulation 103 2001 2822 2827 (Pubitemid 32550071)
15. H. Swan, K. Piippo, and M. Viitasalo Arrhythmic disorder mapped to chromosome 1q42-q43 causes malignant polymorphic ventricular tachycardia in structurally normal hearts J Am Coll Cardiol 34 1999 2035 2042 (Pubitemid 30002662)
16. K.H. Haugaa, I.S. Leren, and K.E. Berge High prevalence of exercise-induced arrhythmias in catecholaminergic polymorphic ventricular tachycardia mutation-positive family members diagnosed by cascade genetic screening Europace 12 2010 417 423
17. U. Mohamed, M.H. Gollob, R.M. Gow, and A.D. Krahn Sudden cardiac death despite an implantable cardioverter-defibrillator in a young female with catecholaminergic ventricular tachycardia Heart Rhythm 3 2006 1486 1489 (Pubitemid 44849373)
18. S. Pizzale, M.H. Gollob, R. Gow, and D.H. Birnie Sudden death in a young man with catecholaminergic polymorphic ventricular tachycardia and paroxysmal atrial fibrillation J Cardiovasc Electrophysiol 19 2008 1319 1321
19. A.A. Wilde, Z.A. Bhuiyan, and L. Crotti Left cardiac sympathetic denervation for catecholaminergic polymorphic ventricular tachycardia N Engl J Med 358 2008 2024 2029 (Pubitemid 351656456)
20. A. Odero, A. Bozzani, G.M. De Ferrari, and P.J. Schwartz Left cardiac sympathetic denervation for the prevention of life-threatening arrhythmias: the surgical supraclavicular approach to cervicothoracic sympathectomy Heart Rhythm 7 2010 1161 1165
21. B. Makanjee, M.H. Gollob, G.J. Klein, and A.D. Krahn Ten-year follow-up of cardiac sympathectomy in a young woman with catecholaminergic polymorphic ventricular tachycardia and an implantable cardioverter defibrillator J Cardiovasc Electrophysiol 20 2009 1167 1169
22. C.A. Collura, J.N. Johnson, C. Moir, and M.J. Ackerman Left cardiac sympathetic denervation for the treatment of long QT syndrome and catecholaminergic polymorphic ventricular tachycardia using video-assisted thoracic surgery Heart Rhythm 6 2009 752 759
23. H. Watanabe, N. Chopra, and D. Laver Flecainide prevents catecholaminergic polymorphic ventricular tachycardia in mice and humans Nat Med 15 2009 380 383
24. F.A. Hilliard, D.S. Steele, and D. Laver Flecainide inhibits arrhythmogenic Ca2+ waves by open state block of ryanodine receptor Ca2+ release channels and reduction of Ca2+ spark mass J Mol Cell Cardiol 48 2010 293 301
25. M.I. Anastasiou-Nana, J.L. Anderson, and J.R. Stewart Occurrence of exercise-induced and spontaneous wide complex tachycardia during therapy with flecainide for complex ventricular arrhythmias: a probable proarrhythmic effect Am Heart J 113 1987 1071 1077 (Pubitemid 17098874)
26. D. Katritsis, E. Rowland, S. O'Nunain, C.F. Shakespeare, J. Poloniecki, and A.J. Camm Effect of flecainide on atrial and ventricular refractoriness and conduction in patients with normal left ventricle Implications for possible antiarrhythmic and proarrhythmic mechanisms Eur Heart J 16 1995 1930 1935
27. R. Rosso, J.M. Kalman, and O. Rogowski Calcium channel blockers and beta-blockers versus beta-blockers alone for preventing exercise-induced arrhythmias in catecholaminergic polymorphic ventricular tachycardia Heart Rhythm 4 2007 1149 1154 (Pubitemid 47324118)
28. D.M. Roden, and R.L. Woosley Drug therapy Flecainide N Engl J Med 315 1986 36 41 (Pubitemid 16093249)
29. C.H. George, G.V. Higgs, and F.A. Lai Ryanodine receptor mutations associated with stress-induced ventricular tachycardia mediate increased calcium release in stimulated cardiomyocytes Circ Res 93 2003 531 540 (Pubitemid 37163233)
30. K. Schlotthauer, and D.M. Bers Sarcoplasmic reticulum Ca(2+) release causes myocyte depolarization Underlying mechanism and threshold for triggered action potentials Circ Res 87 2000 774 780
31. V.A. Maltsev, and E.G. Lakatta Dynamic interactions of an intracellular Ca2+ clock and membrane ion channel clock underlie robust initiation and regulation of cardiac pacemaker function Cardiovasc Res 77 2008 274 284 (Pubitemid 351197645)
32. T.M. Vinogradova, K.Y. Bogdanov, and E.G. Lakatta beta-Adrenergic stimulation modulates ryanodine receptor Ca(2+) release during diastolic depolarization to accelerate pacemaker activity in rabbit sinoatrial nodal cells Circ Res 90 2002 73 79 (Pubitemid 34074611)
33. D.P. Zipes, A.J. Camm, and M. Borggrefe ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death) J Am Coll Cardiol 48 2006 e247 e346
34. M.V. Sherrid, and J.P. Daubert Risks and challenges of implantable cardioverter-defibrillators in young adults Prog Cardiovasc Dis 51 2008 237 263
35. H. Swan, P. Laitinen, K. Kontula, and L. Toivonen Calcium channel antagonism reduces exercise-induced ventricular arrhythmias in catecholaminergic polymorphic ventricular tachycardia patients with RyR2 mutations J Cardiovasc Electrophysiol 16 2005 162 166 (Pubitemid 40326272)
36. R. Rosso, J. Kalman, and O. Rogowsky Long-term effectiveness of beta blocker and calcium blocker combination therapy in patients with CPVT Heart Rhythm 7 2010 S423
37. D.S. Echt, P.R. Liebson, and L.B. Mitchell Mortality and morbidity in patients receiving encainide, flecainide, or placebo The Cardiac Arrhythmia Suppression Trial N Engl J Med 324 1991 781 788